Slider Bild 13Slider Bild 11Slider Bild 9Slider Bild 10Slider Bild 7Slider Bild 3Slider Bild 8Slider Bild 5Slider Bild 4Slider Bild 6Slider Bild 1Slider Bild 2Slider Bild 12

19th ISAD

The International Liver Support Meeting Rostock

Sponsors 2017

Vital Therapies

Vital Therapies, Inc. is a biotherapeutic company developing ELAD®, an investigational extracorporeal human hepatic cell-based LIVER TREATMENT. ELAD is designed to improve survival in patients with LIVER FAILURE by providing hepatic support continuously for up to five days.

The ELAD System incorporates approximately 440 grams of our human liver-derived cells, or VTL C3A cells, contained in four hollow-fiber cartridges, that are combined with disposable components and a reusable delivery device. During treatment with ELAD, blood is drawn from the patient via a central venous line and then passes into the delivery device where plasma ultrafiltrate is isolated. The patient’s plasma ultrafiltrate then passes through hollow fibers contained within the four cartridges, where semipermeable fibers permit bidirectional flow between the VTL C3A cells and the ultrafiltrate. In vitro research suggests that VTL C3A cells add proteins to the ultrafiltrate, and may remove substances typically metabolized by the liver.

Vital Therapies is currently enrolling a phase 3 clinical trial for ELAD in acute alcoholic hepatitis, referred to as VTL-308.  For more information on this trial please visit




ADVOS is the world’s first device for combined multi organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows fluid-based extracorporeal elimination of CO2, hepatic toxins, water, and protein bound renal toxins and correction of metabolic and respiratory acidosis. ADVOS uses regular dialysis vascular access and flow rates.   Common extracorporeal procedures support only one or two organs, the unique approach of ADVOS allows a scalable patient and organ specific support of the 3 main detoxification organs. ADVOS is used mainly on intensive care units with the following indications:   Liver: removal of hepatic toxins Lung: extracorporeal CO₂-removal Kidney: removal of water and additionally protein bound renal toxins Acid-base balance: correction of metabolic and respiratory acidoses with bicarbonate infusion   Founded by nephrologist Bernhard Kreymann in 2005, Hepa Wash today is run by a dynamic and international team and covers all aspects of a certified medical device company with headquarters in Munich, Germany.



Albutec GmbH

Albutec GmbH was founded in 2004 by three associates. Albutec is a research and development company with 6 permanent and some part-time employees. Our company is based in the Hanseatic city of Rostock at the Biomedical Research Center. Albutec developed the Hepalbin®-Adsorbent, which can easily remove unwanted stabilizers from human albumin solutions in order to enhance albumin binding capacity significantly. According to the literature this is associated with a survival benefit for liver patients. The nano structured Hepalbin®-Adsorbent can be used for a bed-side removal of contaminations or to prepare large albumin pools for albumin dialysis, e.g. MARS®. The CE certified infusion device bears the world wide first technology for applying human albumin solutions without caprylate and acetyltryptophanate, which is most important for patients with liver failure. The Hepalbin®-Adsorbent (Cluster) can also deplete substances such as bile acids, bilirubin or creatinine significantly when applied, e.g. for OPAL® (open albumin dialysis). Furthermore, different adsorbent sizes have been evolved in order to fit several patient needs. Albutec is DIN EN ISO 13485 certified. It has authorisation for wholesale trade in medicinal products in accordance with § 52 AMG (German Medicines Act).




NxStage Medical, Inc. is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. NxStage has a history rooted deeply in technology and research. Our inventions and ground breaking technology are helping to improve the lives of kidney patients across the globe and we are just getting started. We are committed not only to research but also education, advocacy, and social responsibility, working closely with our partners, customers, patients, industry leaders, and even in and around our own communities. In short, we are about building next generation dialysis solutions that improve patient quality of life and change the face of renal care across care settings. We love what we do and are here to make a difference.




ALIVER is a project that has received funding from the European Union’s Horizon 2020 research and innovation programme after 25 years of experimental research and data collection on extracorporeal perfusion as a therapy option in liver failure. The ALIVER Consortium has developed and optimised a novel ‘liver dialysis device’, DIALIVE. The Challenge: The incidence of liver disease is increasing and it can lead to liver failure. An estimated 170,000 patients die from liver failure each year in Europe alone. During liver failure, an accumulation of protein-bound toxins and increased susceptibility to infection cause multiorgan failure and death. Liver transplantation is the only treatment, but it is limited by organ availability.




RoweMed AG is an innovative plastic-manufacturing MedTech company. Our focus is on complex customized systems, especially for the handling of sensitive pharmaceuticals. We realize „turnkey“ projects for our customers, from the initial sketch to CAD design and rapid prototyping right through to an approved serial product. For our projects we offer the complete documentation. In our certified clean rooms, we offer injection molding, assembly and packaging from a single source. This is how we realize high-efficiency individual processing, small series and automated large series.




Yaqrit is developing treatments for liver disease. Twenty years of work in liver disease has led to a family of breakthroughs, now combined with experienced management to bring new treatments to liver patients around the world. Our first programmes are for severely ill patients - with cirrhosis or Acute-on-Chronic Liver Failure (ACLF). We plan to broaden our approach to include patients with complication of cirrhosis, Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), which affects more than 25% of populations in developed economies*. *The Burden of Liver Disease in Europe: A review of available epidemiological data, Blachier, J Hepatol. 2013 Mar;58(3):593-608.